In HBV-related HCC, overcoming immune cell evasion involves targeting immunosuppressive mechanisms like LAG3, TIM3, and metabolic adaptations to enhance CD8 T cell response for improved outcomes. The gene discussed is LAG3; the disease is hepatocellular carcinoma.